Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Lofwall

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
The Journal of Continuing Education in the Health Professions|June 17, 2026
Development and Early Outcomes of Interprofessional Education on Opioid Use Disorder in the Kentucky HEALing Communities StudyChristopher D Cook, Katrina Nickels, John A Lauckner, et al.
Journal of Substance Use and Addiction Treatment|December 22, 2025
Cigarette use and smoking cessation goals among pregnant women with opioid use disorderElizabeth E Krans, Daniel Lewis, Antoine Douaihy, et al.
Psychopharmacology|June 9, 2021
Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomesShanna Babalonis, Sandra D Comer, Jermaine D Jones, et al.
Journal of Substance Use and Addiction Treatment|April 6, 2023
Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs studyFrankie B Kropp, Marcela C Smid, Michelle R Lofwall, et al.
Journal of Substance Use and Addiction Treatment|May 13, 2024
Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changesLindsey R Hammerslag, Jeffery Talbert, Svetla Slavova, et al.
Therapeutic Advances in Infectious Disease|July 18, 2022
Design and protocol of the Buprenorphine plus Outpatient Parenteral Antimicrobial Therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infectionsLaura C Fanucchi, Sean M Murphy, Hilary Surratt, et al.
Journal of Addiction Medicine|March 18, 2025
Increasing Initiation of Medications for Opioid Use Disorder Through Recovery Coaches: The Role of Implementation SettingHannah K Knudsen, Amanda Fallin-Bennett, Laura Fanucchi, et al.
Substance Use & Addiction Journal|January 2, 2026
Factors Associated With Opioid-Involved Overdose: Descriptive Data From a Randomized Controlled Trial Evaluating Extended-Release Buprenorphine for Perinatal Opioid Use DisorderSara M Witcraft, Leah Holcomb, Yingjia Wei, et al.
Journal of Clinical Gynecology and Obstetrics|March 4, 2024
What to Expect With Pregnant or Postpartum Prescribing of Extended-Release Buprenorphine (CAM2038)Michelle R Lofwall, Jessica L Young, Zachary Hansen, et al.
Journal of Addiction Medicine|April 10, 2024
Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased MortalityFeitong Lei, Michelle R Lofwall, Jana McAninch, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
The Journal of Continuing Education in the Health Professions|June 17, 2026
Development and Early Outcomes of Interprofessional Education on Opioid Use Disorder in the Kentucky HEALing Communities StudyChristopher D Cook, Katrina Nickels, John A Lauckner, et al.
Journal of Substance Use and Addiction Treatment|December 22, 2025
Cigarette use and smoking cessation goals among pregnant women with opioid use disorderElizabeth E Krans, Daniel Lewis, Antoine Douaihy, et al.
Psychopharmacology|June 9, 2021
Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomesShanna Babalonis, Sandra D Comer, Jermaine D Jones, et al.
Journal of Substance Use and Addiction Treatment|April 6, 2023
Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs studyFrankie B Kropp, Marcela C Smid, Michelle R Lofwall, et al.
Journal of Substance Use and Addiction Treatment|May 13, 2024
Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changesLindsey R Hammerslag, Jeffery Talbert, Svetla Slavova, et al.
Therapeutic Advances in Infectious Disease|July 18, 2022
Design and protocol of the Buprenorphine plus Outpatient Parenteral Antimicrobial Therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infectionsLaura C Fanucchi, Sean M Murphy, Hilary Surratt, et al.
Journal of Addiction Medicine|March 18, 2025
Increasing Initiation of Medications for Opioid Use Disorder Through Recovery Coaches: The Role of Implementation SettingHannah K Knudsen, Amanda Fallin-Bennett, Laura Fanucchi, et al.
Substance Use & Addiction Journal|January 2, 2026
Factors Associated With Opioid-Involved Overdose: Descriptive Data From a Randomized Controlled Trial Evaluating Extended-Release Buprenorphine for Perinatal Opioid Use DisorderSara M Witcraft, Leah Holcomb, Yingjia Wei, et al.
Journal of Clinical Gynecology and Obstetrics|March 4, 2024
What to Expect With Pregnant or Postpartum Prescribing of Extended-Release Buprenorphine (CAM2038)Michelle R Lofwall, Jessica L Young, Zachary Hansen, et al.
Journal of Addiction Medicine|April 10, 2024
Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased MortalityFeitong Lei, Michelle R Lofwall, Jana McAninch, et al.
Pageof 13